-
2023-507461-26-00
5
2022-09-22
Newly diagnosed acute myeloid leukemia (AML)
-
2023-504660-41-00
4
2022-07-11
Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
-
2023-509277-22-00
4
2022-06-22
Bronchiectasis
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-503843-33-00
5
2022-05-04
Coronary Artery Disease
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2024-516392-33-00
5
2021-09-17
Patients (18-75 years) with metastatic and/or refractory soft-tissue
s
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-513950-32-00
4
2020-12-15
Intermediate stage hepatocellular carcinoma (HCC)
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-514962-38-00
1
2020-08-25
Solid Tumors
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-514383-61-00
6
2020-07-07
Diarrhoea predominant irritable bowel syndrome
-
2023-509846-36-00
9
2020-05-29
Advanced Solid Tumors
-
2024-512528-13-00
1
2020-05-27
Multiple System Atrophy
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2024-512104-19-00
6
2019-11-19
Irritable Bowel Syndrome
-
2024-512321-84-00
5
2019-10-02
Patients after HSCT suffering from new or reactivated CMV or EBV or Ad
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma